TeamDrive
RUS

Our projects

Team Drive is engaged in managing two large active projects under cooperation between the  Russian investment corporation RUSNANO which is currently implementing the national policy on the development of high-tech sectors and Domain Associates LLC., a leading US-based venture capital firm with an exclusive focus on life sciences. In March 2012 the partners announced the signing of an agreement to be subject to investments in innovative medical technologies.

To perform this task a subsidiary RMI Partners, a company specializing in managing pharmaceutical and medical projects, has been established by Team Drive.

RusnanoMedInvest

www.rmi.com.ru

RusnanoMedInvest (a subsidiary of RUSNANO) – was founded in March 2012 and is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. Initial funding - $ 380 mln.

Read more...


NovaMedica

www.novamedica.com

NovaMedica is a modern Russian pharmaceutical company established in 2012 by leading U.S. venture capital firm Domain Associates LLC and RUSNANO, an investment fund that implements state policy for the development of Russia’s high-technology industries. NovaMedica's strategy is focused on the search, registration and localization in Russia of innovative pharmaceutical products and technologies, as well as the development of the company’s own research and development activities and the establishment of a GMP-compliant pharmaceutical production facility in Russia.

Read more...


RMI Partners

www.rmivc.com

RMI Patners - a pharmaceutical project management company with a focus on investments to out of the box developments in medical, pharmaceutical and biotechnology sectors worldwide. The company’s key mission – to develop and introduce innovative drugs and medical equipment into the market and to create world-class Russian domiciled expertise in Life Sciences venture financing.

Read more...


The Network of Clinics "Doctor Ryadom"

www.drclinics.ru

Doctor Ryadom is a dynamically developed network of private clinics which was created in Moscow in 2014 by Team Drive and a group of private investors within public-private partnership with Moscow City Government.  The first clinic started its work in April 2014 in a new, densely populous district in South-East of Moscow. In less than a year Doctor Ryadom opened in such areas of Moscow 10 modern, well-equipped, multidimensional clinics for adults and children. 

Read more...

Media Center

  • 24 May 2018

    State Duma adopted a bill to simplify registration of drugs

    It will be possible to register drugs that have the same international nonproprietary names, but different trade names, and being manufactured at the same site. The corresponding government bill No. 327290-7 on amendments to the Federal Law “On Circulation of Medicines” was adopted by the State Duma in the third reading.

  • 23 May 2018

    Today’s realities in the development of local and contract manufacturing

    The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing. Victor Dmitriev, General Director of the Association of Russian Pharmaceutical Manufacturers, said that Russian manufacturers continue to consider the quality of their products as the most important issue.

  • 23 May 2018

    Russian Ministry included the Kirov region biotech cluster in its register

    The Ministry of Industry and Trade of Russia confirmed that the industrial biotechnology cluster of the Kirov region and its specialized organization “The Association of Industrial Biotechnology Cluster” comply with the requirements approved by the Decree of the Russian Government No. 779, dated July 31, 2016.

  • 22 May 2018

    Russian pharmaceutical market: stability in unstable environment

    According to DSM Group, in 2017, the Russian market was worth 1629 billion rubles, which 8% higher than in 2016. For the first time in three years, the market grew in dollar- and euro-denominated terms. In physical terms, the market growth is similar to the dynamics in value terms. Therefore, the factor of higher prices played virtually no role in expanding the market volume. In 2017, the main driver was the increase in the actual consumption of medicinal products, i.e., the growth in terms of sold packages.

Read more